RD114‐pseudotyped retroviral vectors kill cancer cells by syncytium formation and enhance the cytotoxic effect of the TK/GCV gene therapy strategy

Wild‐type RD114 virus is capable of generating syncytia during its replication, and it is believed that cell‐free viruses direct the fusion of neighboring cells. The RD114 envelope (Env) that mediates this fusion event is now widely used to pseudotype retroviral and lentiviral vectors in gene therapy. Indeed, vectors pseudotyped with RD114 Env are very efficient to transfer genes into human hematopoietic cells, and they are resistant to human complement inactivation. In this study, we have tested the potential of RD114‐pseudotyped vectors produced from the FLYRD18 packaging cell line to induce syncytia.

[1]  C. López-Iglesias,et al.  Effects of adenovirus‐mediated SV5 fusogenic glycoprotein expression on tumor cells , 2003, The journal of gene medicine.

[2]  Atique U. Ahmed,et al.  Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. , 2002, Cancer research.

[3]  Atique U. Ahmed,et al.  Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. , 2002, Cancer research.

[4]  J. Qiao,et al.  High translation efficiency is mediated by the encephalomyocarditis virus internal ribosomal entry sites if the natural sequence surrounding the eleventh AUG is retained. , 2002, Human gene therapy.

[5]  C. A. Derdeyn,et al.  Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. , 2001, Human gene therapy.

[6]  E. Vanin,et al.  RD114‐Pseudotyped Oncoretroviral Vectors , 2001, Annals of the New York Academy of Sciences.

[7]  C. James,et al.  Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. , 2001, Human gene therapy.

[8]  Luigi Naldini,et al.  Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.

[9]  C. Souchier,et al.  Higher concentrations of histone macroH2A in the Barr body are correlated with higher nucleosome density , 2000, Current Biology.

[10]  R. Vile,et al.  A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy , 2000, Gene Therapy.

[11]  Jody A. Vandergriff,et al.  Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. , 2000, Blood.

[12]  M. Black,et al.  Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. , 2000, Human gene therapy.

[13]  R. Vile,et al.  Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. , 2000, Cancer research.

[14]  C. Hodgson,et al.  Fusogenic effects of murine retroviruses and cationic enhancers of transduction , 2000, Cancer Gene Therapy.

[15]  M. Black,et al.  Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant , 1999, Gene Therapy.

[16]  C. Tailor,et al.  A Sodium-Dependent Neutral-Amino-Acid Transporter Mediates Infections of Feline and Baboon Endogenous Retroviruses and Simian Type D Retroviruses , 1999, Journal of Virology.

[17]  J. Rasko,et al.  The RD114/simian type D retrovirus receptor is a neutral amino acid transporter. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Morgan,et al.  Development of Improved Adenosine Deaminase Retroviral Vectors , 1998, Journal of Virology.

[19]  R. Vile,et al.  Generation of an anti‐tumour immune response in a non‐immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1‐like profile of intratumoural cytokine expression , 1997, International journal of cancer.

[20]  M. Pyron,et al.  A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. , 1996, Human gene therapy.

[21]  R. Ramesh,et al.  In vivo analysis of the 'bystander effect': a cytokine cascade. , 1996, Experimental hematology.

[22]  Y Takeuchi,et al.  High-titer packaging cells producing recombinant retroviruses resistant to human serum , 1995, Journal of virology.

[23]  R. Grant,et al.  Characterization of infectious type D retrovirus from baboons. , 1995, Virology.

[24]  Y Takeuchi,et al.  Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell , 1994, Journal of virology.

[25]  D. Klatzmann,et al.  Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Garcia,et al.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus , 1991, Journal of virology.

[27]  R. Weiss,et al.  Receptor interference groups of 20 retroviruses plating on human cells. , 1990, Virology.

[28]  K. B. Andersen,et al.  Retrovirus-induced cell fusion is enhanced by protease treatment. , 1989, The Journal of general virology.

[29]  S. Goff,et al.  Construction and use of a safe and efficient amphotropic packaging cell line. , 1988, Virology.

[30]  S. Goff,et al.  A safe packaging line for gene transfer: separating viral genes on two different plasmids , 1988, Journal of virology.

[31]  F. Moolten.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. , 1986, Cancer research.

[32]  A. Miller,et al.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production , 1986, Molecular and cellular biology.

[33]  T. Chen,et al.  Ecotropic murine leukemia virus-induced fusion of murine cells , 1986, Journal of virology.

[34]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[35]  Y. Cheng,et al.  Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. , 1983, The Journal of biological chemistry.

[36]  M. Parker,et al.  Prostatic steroid-binding protein. Isolation and characterization of C3 genes. , 1983, The Journal of biological chemistry.

[37]  E. Hunter,et al.  The characterization of Mason-Pfizer monkey virus-induced cell fusion. , 1979, Virology.

[38]  G. Schidlovsky,et al.  Detection of Mason-Pfizer virus infection with human KC cells carrying Rous virus genome. , 1974, Journal of the National Cancer Institute.

[39]  R. Gilden,et al.  Plaque assay for the Mason-Pfizer monkey virus. , 1974, Journal of the National Cancer Institute.

[40]  K. Rand,et al.  Fusion of a Rous sarcoma virus transformed human cell line, KC, by RD-114 virus. , 1973, The Journal of general virology.

[41]  R. Lerner,et al.  Formation of syncytia in human lymphoblastoid cells infected with type C viruses. , 1973, Virology.

[42]  W. Gallaher,et al.  Preliminary analysis of the requirements for fusion from within and fusion from without by Newcastle disease virus. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Hartley,et al.  Mixed culture cytopathogenicity: a new test for growth of murine leukemia viruses in tissue culture. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Harris,et al.  Hybrid Cells Derived from Mouse and Man : Artificial Heterokaryons of Mammalian Cells from Different Species , 1965, Nature.